Paul M. Palevsky, MD

Paul M. Palevsky, MD, is Professor of Medicine (with tenure), Critical Care Medicine and Clinical and Translational Science in the Renal-Electrolyte Division at the University of Pittsburgh School of Medicine, Chief of the Kidney Medicine Section at the VA Pittsburgh Healthcare System and Deputy National Executive Director for the VHA Kidney Medicine Program. Dr. Palevsky completed his undergraduate and medical education in the Honors Program in Medical Education at Northwestern University followed by internship and residency training in internal medicine and fellowship training in nephrology at the University of Pennsylvania. Dr. Palevsky joined the faculty at the University of Pittsburgh in 1989, where he has remained since.

Dr. Palevsky is a clinical investigator whose research has focused on acute kidney injury (AKI) and critical care nephrology. He was the study chair of the VA/NIH Acute Renal Failure Trial Network (ATN) study (VA CSP #530; NCT00076219) evaluating intensity of renal replacement therapy in critically ill patients with acute kidney injury and the co-chair of the PRESERVE trial (VA CSP #578; NCT01467466), which evaluated the comparative effectiveness of saline and bicarbonate and the efficacy of N-acetylcysteine in preventing kidney damage following angiography, was a member of the steering committee for the EUPHRATES trial (NCT01046669), evaluating the utility of endotoxin adsorption using polymyxin B in patients with severe sepsis and septic shock and was a member of the steering committee for the STARRT-AKI (NCT02568722), comparing accelerated to standard initiation of RRT. He also served as a member of the steering committee of the VA NEPHRON-D study (VA CSP #565; NCT00555217) which compared the effectiveness of combined blockade of the renin-angiotensin system with lisinopril and losartan to monotherapy with losartan on delaying the progression of diabetic kidney disease and the STOP-Gout trial (VA CSP#594; NCT02579096) comparing the safety and effectiveness of allopurinol and febuxostat. He was principal site investigator for the University of Pittsburgh AKI recruitment site for the NIDDK’S Kidney Precision Medicine Project (KPMP; NCT04334707) and is co-principal investigator for the Scientific and Data Research Center for the COPE-AKI study (NCT05805709).

Dr Palevsky has published more than 300 original articles, reviews and book chapters. He has held multiple editorial positions including deputy editor of the Clinical Journal of the American Society of Nephrology, deputy editor of the Journal of the American Society of Nephrology and section editor for Acute Kidney Injury for UpToDate. He is a former member of the board of directors and past chair of the Quality, Safety and Accountability committee of the Renal Physicians Association, is chair of the Medical Review Board of Quality Insights Renal Network 4 (ESRD Network 4), is a past member of board of directors and current member of the Medical Advisory Committee of the Forum of ESRD Networks, is a past-president (2020-2022) of the National Kidney Foundation and is a voting member of the GDA Gastroenterology and Urology Device Panel. Dr. Palevsky is a recipient of the J. Michael Lazarus Award of the National Kidney Foundation and is an elected member of the Association of American Physicians.